EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Pharmacological Evaluation of Sacituzumab Govitecan (IMMU-132) in TROP2-Positive Colorectal Liver Metastasis Models

Weili Zhang iD, Ruowei Wang, Yingting Situ, Weifeng Wang, Jianhong Peng iD, Zhenhai Lu

Pharmaceuticals · 25.07.2026 · 19 (8) · 1163

DOI: 10.3390/ph19081163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 25.07.2026. Verfasst von Weili Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen U…. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Basic and Applied Basic Research Foundation of Guangdong Province, the Beijing Xisike Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Sacituzumab govitecan (SG, IMMU-132) is a TROP2-directed antibody–drug conjugate carrying SN-38. Patients with colorectal liver metastasis (CRLM) still have limited treatment options after first-line systemic therapy, and the preclinical pharmacological value of TROP2-directed SN-38 delivery in CRLM remains insufficiently defined.

Methods

Public single-cell RNA-sequencing data were reanalyzed to explore the distribution of TACSTD2/TROP2-positive epithelial-associated cells in adjacent normal tissues, primary colorectal cancer, and CRLM. The prognostic relevance of TACSTD2 was evaluated using the Kaplan–Meier Plotter database. TROP2-knockdown and TROP2-overexpressing colorectal cancer models were used to assess IMMU-132 response in vitro and in vivo. Pharmacological antitumor activity was further evaluated using subcutaneous xenografts, syngeneic intrasplenic liver metastasis models, and CRLM patient-derived organoids (PDOs). Transcriptomic profiling and γ-H2AX immunofluorescence were used to explore treatment-associated molecular changes.

Results

At the patient/sample level, TACSTD2/TROP2-positive epithelial-associated cells showed numerically higher proportions in primary colorectal tumors and liver metastases than in adjacent normal tissues, and high TACSTD2 expression was associated with inferior overall survival in a public survival database. TROP2 knockdown attenuated IMMU-132-induced growth inhibition, apoptosis, and suppression of colony formation. In vivo, IMMU-132 suppressed colorectal tumor growth and reduced liver metastatic burden, with more evident activity in human TROP2-overexpressing models. In a limited exploratory CRLM PDO cohort established after first-line therapy, liver metastasis-derived PDOs showed lower normalized AUC values than primary tumor-derived PDOs. Transcriptomic analysis and representative γ-H2AX immunofluorescence suggested that IMMU-132 treatment was associated with changes in adhesion/cytoskeletal-related pathways, Wnt/cancer-associated transcriptional programs, and DNA damage-associated signals.

Conclusions

These in vitro, in vivo, and PDO-based findings support further preclinical pharmacological evaluation of TROP2-directed SN-38 delivery by IMMU-132 in biomarker-annotated CRLM models, particularly in the post-first-line systemic therapy setting.

Schlagwörter

Stichwörter der Autor:innen

IMMU-132TACSTD2TROP2antibody–drug conjugatecolorectal liver metastasispatient-derived organoidssacituzumab govitecan

Autor:innen und Institutionen

  • Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, Chi…

ORCID-Profile: Weili Zhang, Jianhong Peng

Förderung

  • the Basic and Applied Basic Research Foundation of Guangdong Province
  • the Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Zhang, W., Wang, R., Situ, Y., Wang, W., Peng, J., & Lu, Z. (2026). Preclinical Pharmacological Evaluation of Sacituzumab Govitecan (IMMU-132) in TROP2-Positive Colorectal Liver Metastasis Models. Pharmaceuticals, 19(8), 1163. https://doi.org/10.3390/ph19081163

Vancouver

Zhang W, Wang R, Situ Y, Wang W, Peng J, Lu Z. Preclinical Pharmacological Evaluation of Sacituzumab Govitecan (IMMU-132) in TROP2-Positive Colorectal Liver Metastasis Models. Pharmaceuticals. 2026;19(8):1163. doi:10.3390/ph19081163

BibTeX
@article{Zhang2026,
  author = {Zhang, Weili and Wang, Ruowei and Situ, Yingting and Wang, Weifeng and Peng, Jianhong and Lu, Zhenhai},
  title = {Preclinical Pharmacological Evaluation of Sacituzumab Govitecan (IMMU-132) in TROP2-Positive Colorectal Liver Metastasis Models},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1163},
  doi = {10.3390/ph19081163}
}
Kostenlos starten →